Association between lipid profile changes and risk of in-stent restenosis in ischemic stroke patients with intracranial stenosis: A retrospective cohort study

Abstract

Objective

The risk of ischemic stroke with intracranial stenosis is associated with various serum lipid levels. However, the effects of changes in the lipid profile on the risk of in-stent restenosis have not been verified. Therefore, we investigated the association between the occurrence of in-stent restenosis at 12-month follow-up and changes in various lipid profiles.

Methods

In this retrospective cohort study, we included ischemic stroke patients who had undergone intracranial stenting for symptomatic intracranial stenosis between February 2010 and May 2020. We collected data about serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglyceride (TG) levels, and calculated the TC/HDL-C and LDL-C/HDL-C ratios at baseline and after 12 months. We conducted multivariable logistic regression analyses to verify the association between various lipid profile changes and in-stent restenosis at 12 months.

Results

Among the 100 patients included in the study (mean age, 60.8 ± 10.0 years; male: 80 [80.0%]), in-stent restenosis was found in 13 (13.0%) patients. The risk of in-stent restenosis of more than 50% was significantly decreased when TC/HDL-C ratio (odds ratio [OR] 0.22, [95% confidence interval (CI) 0.05–0.87]) and LDL-C/HDL-C ratio (OR 0.23, [95% CI 0.06–0.93]) decreased or when HDL-C levels (OR 0.10, [95% CI 0.02–0.63]) were increased at 12 months compared with baseline measurements.

Conclusions

Improvement of HDL-C levels, TC/HDL-C ratio, and LDL-C/HDL-C ratio were associated with decreased risk of in-stent restenosis at 12-month follow-up. Management and careful monitoring of various lipid profiles including HDL-C levels, TC/HDL-C ratio, and LDL-C/HDL-C ratio may be important to prevent in-stent restenosis in patients with intracranial stenting.

Introduction

Intracranial angioplasty and stenting can be considered for cases refractory to optimal medical treatment [1, 2]. The incidence of in-stent restenosis (ISR) is as high as 30% [3, 4]. Previous studies showed that lowering low-density lipoprotein cholesterol (LDL-C) levels may have a beneficial effect in patients with intracranial and extracranial artery stenosis [5, 6]. Also, statins reduced the risk of cardiovascular events in patients who underwent carotid revascularization [7].

Moreover, it was recently reported that various lipid profiles affect carotid artery restenosis after carotid endarterectomy or stenting [8]. Furthermore, other lipid profiles, such as the total cholesterol (TC)/LDL-C and LDL-C/high-density lipoprotein cholesterol (HDL-C) ratios, are associated with the risk of cardiovascular disease [9, 10]. However, only few studies have reported the effects of various lipid profiles on the prognosis of revascularization and ISR after intracranial stenting.

The purpose of the current study was to investigate the association between various lipid profiles including LDL-C and HDL-C levels, and TC/HDL-C and LDL-C/HDL-C ratios after statin treatment and the occurrence of ISR in patients who underwent intracranial stenting. We also investigated the association between the improvement of these lipid profiles and ISR after a 12-month follow-up.

Methods

Participants

We retrospectively reviewed the medical records of all patients with symptomatic intracranial stenosis who underwent intracranial stenting between February 2010 and May 2020 at Asan Medical Center (Seoul, South Korea). We included patients who fulfilled the following criteria: (1) age >18 years, (2) ischemic stroke or transient ischemic attack in the previous 6 months, and (3) stenosis of anterior circulation intracranial artery of at least 70%. We excluded patients who had a premorbid moderate-to-severe disability (modified Rankin scale score > 3). Demographic, vascular risk factors, and related laboratory data were obtained at baseline. This study was approved by the institutional review board of Asan Medical Center (IRB No. 2020–0726), which waived the need for written informed consent considering the retrospective nature of the study.

Measurement of serum lipid profiles

We collected serum lipid samples at baseline and follow-up visits after 12 months. Serum lipid sampling was obtained after an overnight 12-hour fast because LDL-C, HDL-C, TC, and triglyceride (TG) levels are increased 3–6 hours after a meal. Based on the serum lipid measurements, we calculated the TC/HDL-C and LDL-C/HDL-C ratios. From this data, we dichotomized the lipid profiles according to whether these parameters improved. Improvement of TC, TG, and LDL-C levels, TC/HDL-C ratio, and LDL-C/HDL-C ratio was defined as a decrease at 12 months after baseline measurements, while improvement of HDL-C was defined as an increase at 12 months after baseline measurements.

High-intensity statin was defined as a reduction in LDL-C of >50% according to the 2013 American College of Cardiology/American Heart Association guideline. Administration of atorvastatin 40–80 mg or rosuvastatin 20–40 mg was classified as high-intensity statin therapy. Statin intensity was dichotomized into high intensity and low-to-moderate intensity.

Stent procedure and follow-up intracranial neurovascular imaging

All patients received aspirin (100 mg/day) and clopidogrel (75 mg/day) for at least 7 days before procedure. The stenting procedure was performed under local anesthesia by experienced neuro-interventionists who chose the types of catheters, guidewires, and stents. Most intracranial stenting procedures were performed using the Wingspan^® (Boston Scientific Corporation, Fremont, CA, USA), Enterprise^® (Codman Neurovascular, Raynham, MA, USA), and Vision^® (Abbott Vascular, Santa Clara, CA, USA). After stent insertion, dual antiplatelet therapy was maintained at the discretion of the treating physician for at least 3–6 months [11].

Intracranial neurovascular imaging was performed using magnetic resonance angiography (MRA), computed tomography angiography (CTA), or digital subtraction angiography (DSA). Neurovascular imaging was performed on the day after intracranial stenting, and at the 12-month follow-up. The severity of intracranial artery stenosis before stent insertion was calculated by dividing the residual diameter by the vessel diameter at a point distal to the stenosis to obtain the normal vessel diameter. The severity of ISR was calculated by dividing the residual diameter at 12-month follow-up imaging by the residual stenosis measured right after stent insertion. According to the severity, ISR was defined as follows: mild (≤ 50%), moderate (50–70%), and severe stenosis or occlusion (70%–100%). The main outcome was the presence of more than 50% of restenosis in neurovascular imaging at 12-month follow-up after stent insertion. Outcomes for sensitivity analysis included the degree of ISR measured as an ordinal variable (mild, moderate, and severe stenosis or occlusion) and any degree of restenosis.

Statistical analysis

The baseline characteristics of study patients were analyzed. Then, we stratified patients according to the presence of stenosis at follow-up neurovascular imaging and compared according to clinical characteristics and various serum lipid profiles and their changes (TC, TG, HDL-C, and LDL-C levels, and LDL-C/HDL-C and TC/HDL-C ratios). Continuous variables are presented as mean ± standard deviation (SD), while categorical variables are presented as frequency and percentage. The significance of intergroup differences was assessed using Pearson’s chi-square test, Fisher’s exact test, and Student’s t-test, as appropriate.

Improvement of serum lipid profiles was entered into multivariable binary and ordinal logistic regression analyses to identify the independent associations with the outcomes as described above. Model 1 was unadjusted. Model 2 was adjusted for age and sex. Model 3 was adjusted for age, sex, and statin intensity (low-to-moderate intensity vs. high intensity) considering that these factors are regarded to be clinically important. The odds ratios (ORs) are presented with 95% confidence intervals (CI). All analyses were performed using R (version 4.0.5; R Foundation for Statistical Computing, Vienna, Austria).

Results

During the study period, 100 patients underwent intracranial stenting for symptomatic severe stenosis refractory to medical treatment and were included in the analysis (Fig 1). Before stent insertion, all patients underwent DSA to calculate the severity of intracranial artery stenosis. At the 12-month follow-up after stent insertion, most patients (72%) underwent CTA for neurovascular imaging, followed by MRA (18%) and DSA (10.0%).

[Figure omitted. See PDF.]

Baseline characteristics of patients with intracranial stent insertion

The clinical characteristics of the study patients are summarized in Table 1. The mean age was 60.8±10.0 years, and 80 (80.0%) were male. Of them, 50 (50.0%) patients were prescribed high-intensity statins. Neurovascular imaging at 12-month follow-up revealed ISR in 13 (13.0%) patients (mild: 2 [2.0%], moderate: 7 [7.0%], severe stenosis or occlusion: 4 [4.0%]). Most of the stents were inserted into the middle cerebral artery (56 [56.0%]) and distal internal carotid artery (43 [43.0%]). Among the 13 patients with ISR, five patients had acute neurological deterioration when ISR was found. Three patients had a recurrent acute ischemic stroke in the stented territory, and two patients had a transient ischemic attack related to the stented territory. The types of stents used in the procedure were: Wingspan^® (55.0%), Enterprise^® (17.0%), Vision^® (15.0%), and others (14.0%).

[Figure omitted. See PDF.]

Baseline characteristics according to the presence of ISR > 50%

The comparison of clinical characteristics is summarized according to the presence of ISR > 50% (Table 2). Except for the younger mean age in the ISR > 50% group (61.8 ± 9.7 years vs. 53.5 ± 10.1 years, P = 0.009), there were no significant differences in sex, vascular risk factors, and statin intensity between the two groups. The LDL-C levels, TC/HDL-C ratios, and LDL-C/HDL-C ratios were significantly higher at baseline in patients with ISR ≤ 50% (P = 0.032, P = 0.046, and P = 0.036, respectively). There were no significant differences in the improvement of various lipid profiles between the two groups.

[Figure omitted. See PDF.]

Association between various serum lipid profiles after statin treatment and ISR

The associations between various outcomes and variables with the presence of ISR > 50% are summarized in Table 3. Improvements in HDL-C levels (OR 0.10 [95% CI, 0.02–0.63], P = 0.014), TC/HDL-C ratio (OR 0.22 [95% CI, 0.05–0.87], P = 0.031), and LDL-C/HDL-C ratio (OR 0.23 [95% CI, 0.06–0.93], P = 0.039) were significantly associated with the occurrence of ISR > 50% in Model 3 adjusted age, sex, and statin intensity.

[Figure omitted. See PDF.]

When the outcome was dichotomized according to the occurrence of ISR, the association with the improvement of HDL-C levels (OR 0.16 [95% CI, 0.03–0.76], P = 0.021) and LDL-C/HDL-C ratio was maintained (OR 0.26 [95% CI, 0.07–0.96], P = 0.043). Ordinal logistic regression analyses also showed a consistent trend for the improvement in HDL-C levels (OR 0.17 [95% CI, 0.04–0.78], P = 0.023) and the LDL-C/HDL-C ratio (OR 0.28 [95% CI, 0.08–1.03], P = 0.055).

Additionally, we investigated the association between the discordance of LDL-C levels and the occurrence of ISR. Of the 50 patients with LDL-C levels below the median LDL-C level, which were regarded as being well-controlled, 43 patients had lower non-HDL-C levels (concordant) and the remaining seven patients had higher non-HDL-C levels (discordant). ISR was observed in eight patients (18.6%) in the concordant group and in two patients (28.6%) in the discordant group (P = 0.481) (S1 Table).

Discussion

This study showed that improvements in HDL-C levels and TC/HDL-C and LDL-C/HDL-C ratios decreased the risk of the occurrence of ISR > 50% at 12-month follow-up. The association was maintained when the outcome was changed to the occurrence of ISR or analyzed as an ordinal variable (mild, moderate, and severe degree of restenosis). Unlike previous studies that investigated lipid measurements at one time point, we have longitudinally measured and analyzed the changes in various lipid profiles between baseline and at 12-month follow-up.

In previous studies, baseline lipid parameters were shown to be positively associated with cardiovascular disease [12–14]. Contrary to these prior studies, baseline LDL-C levels and TC/HDL-C and LDL-C/HDL-C ratios were significantly lower in the restenosis group in the current study. This may be due to the fact that patients without ISR had higher LDL-C levels before the administration of statin than those with ISR. Therefore, more patients without ISR received high-intensity statin within the preprocedural period. After 12 months of statin treatment, there was no significant difference in LDL-C levels between the two groups, suggesting that using high-intensity statins during a periprocedural period not only reduces the risk of periprocedural stroke but may also reduce the long-term risk of ISR.

ISR results from neo-intimal hyperplasia and early-stage vascular remodeling [15]. Proliferation and migration of vascular smooth muscle cells were suggested as the main causes for neo-intimal hyperplasia after stent insertion [16]. Also, elevated high-sensitive C-reactive protein, one of the biomarkers in systemic inflammation, was associated with ISR in coronary intervention [17]. Statins exert a diverse range of pleiotropic effects against these restenosis cascades, such as the inhibition of vascular smooth muscle cell proliferation, improvement of endothelial dysfunction, stabilization of atherosclerotic plaques, inhibition of platelet aggregation and intravascular inflammation, and enhanced anti-oxidative processes [18, 19]. Thus, using high-intensity statin during a periprocedural period may be as important as using antiplatelet drugs for preventing ISR.

Recently, there has been growing interest in the predictive role of lipid profiles on cardiovascular outcomes. Atherogenic lipoprotein particle number or concentration measured via nuclear magnetic resonance is more closely related to cardiovascular risk than LDL-C levels. Similar results have been described with standard lipid panels including the TC/HDL-C ratio, apolipoprotein B100 levels, and non-HDL-C levels [20]. The residual cardiovascular risk after statin therapy is more strongly associated with non-HDL-C than with LDL-C or apolipoprotein-B levels [21]. Previous studies showed that the LDL-C/HDL-C ratio is a better predictor for ischemic stroke events or outcomes [22]. Although the mechanism of improved prediction remains to be verified, several explanations are possible. It is known that intracranial arteries have a higher antioxidant capacity and are more prone to oxidative stress than extracranial arteries [23]. HDL-C inhibits the oxidation of phospholipids and the oxidant activity of LDL-C, and low HDL-C levels may increase oxidative stress to a higher degree in intracranial arteries than in extracranial arteries [24]. Intracranial artery stenosis is associated with insulin resistance. Insulin resistance is related to higher fasting TG level and low HDL-C level [25, 26]. Therefore, including HDL-C or non-HDL-C beyond LDL-C may be more sensitive for predicting ISR.

Beyond various lipid profiles, we analyzed the effects of discordance of LDL-C. The prevalence of discordance between LDL-C and other lipid parameters ranges from 11% to 25%, and the cardiovascular risk may be over- or under-estimated in such patients. Although the risk of ISR was higher in patients with discordance between LDL-C and non-HDL-C, there was no statistical significance between the two groups due to the small number of patients.

Our study has several limitations. First, because this study was conducted only in a single race with a small sample size, the generalizability is limited even if we adjusted for some factors in multivariable models. Also, we could not perform a statistical power calculation because of the retrospective nature of this study as well as its main goal. These findings require further verification in a larger prospective study. Second, because lipid profiles were measured only twice, we could not calculate the variability parameters exactly. Third, although we adjusted for some clinical factors in multivariable logistic regression analysis, we could not consider other confounding factors such as food intake, dietary habit, and physical activity that can affect serum lipid profiles. Finally, we cannot exclude the possibility that some ISRs had already occurred before checking the lipid profiles at 12 months.

Despite these limitations, we have shown that improvements in various lipid profiles were associated with the occurrence of ISR at 12-month follow-up. Therefore, management and careful monitoring of various lipid profiles beyond LDL-C levels may be important to prevent ISR in patients with intracranial stenting.

Supporting information

S1 Table. Association between the discordance of LDL-C levels and the occurrence of ISR in patients with LDL-C levels below the median LDL-C level.

https://doi.org/10.1371/journal.pone.0284749.s001

(DOCX)

Citation: Ryu J-C, Bae J-H, Ha SH, Kwon B, Song Y, Lee DH, et al. (2023) Association between lipid profile changes and risk of in-stent restenosis in ischemic stroke patients with intracranial stenosis: A retrospective cohort study. PLoS ONE 18(5): e0284749. https://doi.org/10.1371/journal.pone.0284749

About the Authors:

Jae-Chan Ryu

Roles: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ORICD: https://orcid.org/0000-0002-0935-963X

Jae-Han Bae

Roles: Methodology, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Sang Hee Ha

Roles: Methodology, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Boseong Kwon

Roles: Methodology, Writing – review & editing

Affiliation: Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ORICD: https://orcid.org/0000-0002-6113-9730

Yunsun Song

Roles: Methodology, Writing – review & editing

Affiliation: Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Deok Hee Lee

Roles: Methodology, Writing – review & editing

Affiliation: Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Bum Joon Kim

Roles: Methodology, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ORICD: https://orcid.org/0000-0002-3278-3252

Dong-Wha Kang

Roles: Methodology, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Sun U. Kwon

Roles: Methodology, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Jong S. Kim

Roles: Methodology, Writing – review & editing

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Jun Young Chang

Roles: Conceptualization, Investigation, Methodology, Writing – review & editing

E-mail: [email protected]

Affiliation: Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ORICD: https://orcid.org/0000-0003-4880-9258

References

1. Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12): 1240–1248. pmid:25803346

2. Yu W, Jiang WJ. Stenting for intracranial stenosis: potential future for the prevention of disabling or fatal stroke. Stroke Vasc Neurol. 2018;3(3): 140–146. pmid:30294469

3. Marks MP, Wojak JC, Al-Ali F, Jayaraman M, Marcellus ML, Connors JJ, et al. Angioplasty for symptomatic intracranial stenosis: clinical outcome. Stroke. 2006;37(4): 1016–1020. pmid:16497979

4. Levy EI, Turk AS, Albuquerque FC, Niemann DB, Aagaard-Kienitz B, Pride L, et al. Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery. 2007;61(3): 644–650; discussion 650–641. pmid:17881980

5. Chung JW, Cha J, Lee MJ, Yu IW, Park MS, Seo WK, et al. Intensive Statin Treatment in Acute Ischaemic Stroke Patients with Intracranial Atherosclerosis: a High-Resolution Magnetic Resonance Imaging study (STAMINA-MRI Study). J Neurol Neurosurg Psychiatry. 2020;91(2): 204–211. pmid:31371644

6. Brinjikji W, Lehman VT, Kallmes DF, Rabinstein AA, Lanzino G, Murad MH, et al. The effects of statin therapy on carotid plaque composition and volume: A systematic review and meta-analysis. J Neuroradiol. 2017;44(4): 234–240. pmid:28187866

7. Hussain MA, Saposnik G, Raju S, Salata K, Mamdani M, Tu JV, et al. Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization. J Am Heart Assoc. 2018;7(16): e009745. pmid:30369318

8. Hong JH, Sohn SI, Kwak J, Yoo J, Chang HW, Kwon OK, et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke. 2017;48(7): 1890–1894. pmid:28626049

9. Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr. 2008;27(1): 1–5. pmid:18460475

10. Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5: 757–765. pmid:19774217

11. Sussman ES, Jin M, Pendharkar AV, Pulli B, Feng A, Heit JJ, et al. Dual antiplatelet therapy after carotid artery stenting: trends and outcomes in a large national database. J Neurointerv Surg. 2021;13(1): 8–13. pmid:32414894

12. Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and high-density lipoprotein cholesterol and stroke risk. Stroke. 2012;43(7): 1768–1774. pmid:22496337

13. Fujihara K, Suzuki H, Sato A, Kodama S, Heianza Y, Saito K, et al. Carotid artery plaque and LDL-to-HDL cholesterol ratio predict atherosclerotic status in coronary arteries in asymptomatic patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2013;20(5): 452–464. pmid:23363982

14. Park JH, Lee J, Ovbiagele B. Nontraditional serum lipid variables and recurrent stroke risk. Stroke. 2014;45(11): 3269–3274. pmid:25236873

15. Goel SA, Guo LW, Liu B, Kent KC. Mechanisms of post-intervention arterial remodelling. Cardiovasc Res. 2012;96(3): 363–371. pmid:22918976

16. Campbell JH, Campbell GR. Smooth muscle phenotypic modulation—a personal experience. Arterioscler Thromb Vasc Biol. 2012;32(8): 1784–1789. pmid:22815344

17. Baktashian M, Saffar Soflaei S, Kosari N, Salehi M, Khosravi A, Ahmadinejad M, et al. Association of high level of hs-CRP with in-stent restenosis: A case-control study. Cardiovasc Revasc Med. 2019;20(7): 583–587. pmid:30232022

18. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1): Iii39–43. pmid:15198965

19. Liberale L, Carbone F, Montecucco F, Sahebkar A. Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms. Int J Biochem Cell Biol. 2020;122: 105735. pmid:32126319

20. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7): 931–939. pmid:19204302

21. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12): 1302–1309. pmid:22453571

22. Liu L, Yin P, Lu C, Li J, Zang Z, Liu Y, et al. Association of LDL-C/HDL-C Ratio With Stroke Outcomes Within 1 Year After Onset: A Hospital-Based Follow-Up Study. Front Neurol. 2020;11: 408. pmid:32499753

23. D’Armiento FP, Bianchi A, de Nigris F, Capuzzi DM, D’Armiento MR, Crimi G, et al. Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke. 2001;32(11): 2472–2479. pmid:11692003

24. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8): 764–772. pmid:15486323

25. Park HY, Kyeong H, Park DS, Lee HS, Chang H, Kim YS, et al. Correlation between insulin resistance and intracranial atherosclerosis in patients with ischemic stroke without diabetes. J Stroke Cerebrovasc Dis. 2008;17(6): 401–405. pmid:18984435

26. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231(1): 25–30. pmid:1732395